New Collaboration to Advance TIL Therapies
xsmb kết quả xổ số miền bắc hôm nayMD Anderson and Obsidian Therapeutics announced a multi-year strategic collaboration to expedite the research and development of novel engineered tumor-infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian’s novel technology platform with MD Anderson’s extensive experience and capabilities, led by the Biologics Development platform.